GlassScriptPhysician profile
John M Reyes
NPI 1578820031
$2,695.12
in general payments reported to CMS, 2019-2025
17 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $53.95 · 2021: $78.01 · 2022: $278 · 2023: $727 · 2024: $393 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $790.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $316.29 | 2019-2025 | |
| Abbvie INC. | $306.32 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $206.88 | 2019-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $198.63 | 2019-2025 | Gardasil 9, Verquvo, Capvaxive |
| Regeneron Healthcare Solutions, INC. | $164.44 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $146.85 | 2023 | Arexvy |
| Abbott Laboratories | $142.10 | 2019-2021 | |
| Lilly USA, LLC | $138.00 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $55.22 | 2023-2025 | Veozah |
| Amarin Pharma, INC. | $55.14 | 2019-2020 | |
| Genzyme Corporation | $48.78 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $37.34 | 2021-2024 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $26.86 | 2023 | Livalo, Seglentis |
| Dexcom, INC. | $21.37 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.84 | 2023 | Xarelto |
| Amgen INC. | $19.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.